Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Joint Venture, Subsidiary

Established: 1997-04-16

Employees: -

Market Cap: -

Website: http://www.cttq.com

Clinical Trials

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Phase 3

Conditions: Advanced Biliary Cancer

Interventions: Drug: Oxaliplatin injection
Drug: TQB2450 Injection
Drug: Anlotinib hydrochloride
Drug: Capecitabine tablets
Drug: Gemcitabine hydrochloride injection

First Posted Date: 2021-03-22

Last Posted Date: 2021-03-22

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 392

Registration Number: NCT04809142

Locations: 🇨🇳
Harbin Medical University Affiliated Tumor Hospital, Harbin, Heilongjiang, China
🇨🇳
Anhui Provincal Hospital, Hefei, Anhui, China
🇨🇳
Cangzhou Central Hospital, Cangzhou, Hebei, China

and more 14 locations

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetic Study

Interventions: Drug: TQ-B3101

First Posted Date: 2021-03-18

Last Posted Date: 2022-01-21

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT04804904

Locations: 🇨🇳
Zhongshan Hospital of Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors

Phase 1

Recruiting

Conditions: Terminal Malignant Tumors

Interventions: Drug: TQB2858 injection

First Posted Date: 2021-03-18

Last Posted Date: 2021-06-04

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT04805060

Locations: 🇨🇳
Jinlin Cancer Hospital, Changchun, Jilin, China

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Phase 2

Conditions: HR-positive, HER2-negative Advanced Breast Cancer

Interventions: Drug: TQB3616 capsules
Drug: Fulvestrant injection

First Posted Date: 2021-03-15

Last Posted Date: 2021-03-15

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04796623

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳
Gansu Provincial Hostipal, Lanzhou, Gansu, China
🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China

and more 14 locations

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Phase 1

Conditions: Hemophilia B With Inhibitor
Hemophilia A With Inhibitor

Interventions: Drug: TQG203
Drug: TQG203/NovoSeven®

First Posted Date: 2021-02-24

Last Posted Date: 2021-02-24

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT04768699

Locations: 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: TQ-B3139 capsules

First Posted Date: 2020-12-19

Last Posted Date: 2021-04-01

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT04675060

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Phase 2

Conditions: Recurrent or Metastatic Cervical Cancer

Interventions: Drug: TQB2450

First Posted Date: 2020-11-10

Last Posted Date: 2020-11-10

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT04623333

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shangdong, China

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumors

Interventions: Drug: TQB2618 injection

First Posted Date: 2020-11-10

Last Posted Date: 2020-11-10

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT04623892

Locations: 🇨🇳
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

Phase 2

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: TQ-B3525

First Posted Date: 2020-11-04

Last Posted Date: 2020-11-04

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 78

Registration Number: NCT04615468

Locations: 🇨🇳
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）

Phase 2

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: TQ-B3525 tablets

First Posted Date: 2020-11-02

Last Posted Date: 2021-08-18

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 93

Registration Number: NCT04610970

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy